Transformative Clinical Findings from Xeltis
Xeltis recently announced exhilarating results from its pivotal aXess EU trial, which indicate the potential for significant advancements in hemodialysis treatment. By focusing on their revolutionary implant technology, Xeltis aims to improve outcomes for patients battling end-stage renal disease.
The aXess EU Pivotal Trial Overview
This seminal study presents a detailed evaluation of the aXess device, developed specifically for creating a vascular access conduit necessary for patients undergoing hemodialysis. Conducted across 18 sites in Europe, the trial investigated the safety and patency of aXess in adult patients, many of whom were previously underserved due to a lack of successful grafts.
Significant Improvements in Key Metrics
The results of the aXess trial show marked improvements over the traditional standard of care, evidencing superior sustained patency rates across both primary and secondary outcomes. Notably, fewer interventions were required, and patients experienced lower rates of infection and complications as compared to traditional arteriovenous grafts (AVG) and fistulas. Many of the trial participants had faced multiple failed interventions, highlighting the importance of these findings.
Voices from Xeltis Leadership
Eliane Schutte, Chief Executive Officer at Xeltis, expressed confidence in the potential of aXess, stating, "These results reinforce our belief that aXess is the future of hemodialysis vascular access. With its outstanding clinical performance and absence of PFAS, we are ready to advance to commercialization, benefiting patients and caregivers alike."
Paulo Neves, Chief Medical Officer, also emphasized the collaborative nature of the trial, thanking all involved—from researchers to clinicians to patients—highlighting that the results are transformative for Xeltis as they prepare to launch their market strategy.
Innovative Technology Behind aXess
aXess is developed using Xeltis’ proprietary Endogenous Tissue Restoration (ETR) technology. This innovative approach utilizes groundbreaking polymer technology to encourage the patient’s body to regenerate its own tissue, gradually integrating the devise into a living blood vessel over time. With only one minor infection related to cannulation observed across the entire participant group, aXess has emerged as a high-performing solution, enabling immediate cannulation with minimal complications during extensive dialysis sessions.
The Road Ahead: US Pivotal Trial and Future Developments
As Xeltis gears up for commercialization, they are also running a pivotal trial in the United States, with recruitment efforts progressing and interim results anticipated soon. These simultaneous efforts place Xeltis at the forefront of innovation in vascular treatment options.
About Xeltis
Xeltis is a medtech company dedicated to developing implants that foster the natural creation of long-lasting blood vessels. Targeting the needs of countless individuals requiring hemodialysis access and cardiovascular replacements, Xeltis’ ETR platform uniquely focuses on regenerating the patient’s own tissue, ensuring seamless integration and sustainability. Their leading product, aXess, is currently in the clinical development phase, poised to transform hemodialysis assistance and potentially address a range of cardiovascular ailments.
Located in both Europe and the USA, Xeltis is backed by notable investors including DaVita Venture Group and EQT Life Sciences among others, solidifying its stature as a pioneer in the medtech sector.
Frequently Asked Questions
What is the aXess EU pivotal trial?
The aXess EU pivotal trial is a clinical study that investigates the safety, efficacy, and performance of the aXess device for hemodialysis vascular access in patients with end-stage renal disease.
What were the main results of the trial?
The trial showed aXess achieving higher sustained patency rates and fewer interventions required compared to traditional methods, offering a promising solution for patients needing vascular access.
How does aXess differ from traditional vascular access methods?
aXess utilizes Endogenous Tissue Restoration technology, promoting the growth of the patient's own tissue around the implant, whereas traditional methods often rely on synthetic materials.
What is Xeltis' future plan following these results?
Xeltis plans to commercialize aXess based on these results while continuing to evaluate its performance in US pivotal trials.
What is the significance of these clinical findings?
These findings signify a groundbreaking advancement for hemodialysis treatment options, potentially transforming how patients receive safe and effective vascular access.
